Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate ABVC BioPharma, Inc. before investing.

In this article, we go over a few key elements for understanding ABVC BioPharma, Inc.’s stock price such as:

• ABVC BioPharma, Inc.’s current stock price and volume
• Why ABVC BioPharma, Inc.’s stock price changed recently
• Upgrades and downgrades for ABVC from analysts
• ABVC’s stock price momentum as measured by its relative strength

About ABVC BioPharma, Inc. (ABVC)

Before we jump into ABVC BioPharma, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.

Want to learn more about ABVC BioPharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about ABVC BioPharma, Inc..

ABVC BioPharma, Inc.’s Stock Price as of Market Close

As of May 21, 2026, 4:00 PM, CST, ABVC BioPharma, Inc.’s stock price was $1.110.

ABVC BioPharma, Inc. is up 0.91% from its previous closing price of $1.100.

During the last market session, ABVC BioPharma, Inc.’s stock traded between $1.020 and $1.150. Currently, there are approximately 25.45 million shares outstanding for ABVC BioPharma, Inc..

ABVC BioPharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

ABVC BioPharma, Inc. Stock Price History

ABVC BioPharma, Inc.’s (ABVC) price is currently up 7.77% so far this month.

During the month of May, ABVC BioPharma, Inc.’s stock price has reached a high of $1.160 and a low of $0.998.

Over the last year, ABVC BioPharma, Inc. has hit prices as high as $5.480 and as low as $0.880. Year to date, ABVC BioPharma, Inc.’s stock is down 47.89%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused ABVC BioPharma, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 20, 2026, there were analysts who downgraded ABVC BioPharma, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate ABVC BioPharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on ABVC BioPharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about ABVC BioPharma, Inc. (ABVC) by visiting AAII Stock Evaluator.

Relative Price Strength of ABVC BioPharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 20, 2026, ABVC BioPharma, Inc. has a weighted four-quarter relative price strength of -2.83%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how ABVC BioPharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

ABVC BioPharma, Inc. Stock Price: Bottom Line

As of May 21, 2026, ABVC BioPharma, Inc.’s stock price is $1.110, which is up 0.91% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like ABVC BioPharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.